Curevo’s lead asset, amezosvatein, is a Phase 3-ready shingles vaccine with potential to increase vaccination rates by delivering improved tolerability versus approved products Seattle, WA – May 26, 2026 – Curevo Vaccine (Curevo), a clinical-stage biotechnology company dedicated to developing varicella zoster virus (VZV) vaccines with improved tolerability, today announced entry into a definitive…Read More
We engaged FLG Partners in early 2018 to assist us with a CFO transition, to mentor and build-out the Finance team, as well as to address and resolve certain complex finance and tax issues. Our FLG Partner, Laureen DeBuono, has spent the year working with me and our HotelTonight team closely, and we have built a world-class Finance team, resolved the prior finance and tax issues, and are poised for continued strong success and growth. I have been very pleased with the skills and “gravitas” that our FLG Partner brought to the assignment.
